+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
10 Mar 2016

Technology Licensing Case Study: Peptiderm’s licensing of PDPS technology to Lilly

Technology transfer, also called transfer of technology (TOT), is the process of transferring skills, knowledge, technologies, methods of manufacturing, samples of manufacturing and facilities among governments or universities and other institutions to ensure that scientific and technological developments are accessible to a wider range of users who can then further develop and exploit the technology into new products, processes, applications, materials or services.

PeptiDream Inc., a public Tokyo-based biopharmaceutical company, has entered into a technology license agreement with US-based Eli Lilly and Company to non exclusively license PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology.

Under the terms of the technology license agreement, PeptiDream will receive upfront and annual technology access payments, and will be eligible to receive development milestones and royalties on future sales of products (both peptide and small molecule therapeutics) that arise from use of the PDPS technology. Similar to previous technology licenses, the license will exclude work on peptide-drug conjugate (PDC) programmes, as PeptiDream has extensive internal development efforts ongoing in this area, to which PeptiDream will be providing additional information soon.

PeptiDream will continue to work with Lilly to identify and develop potential drug candidates for Lilly’s targets using PeptiDream’s PDPS technology, under the original agreement in December 2013, in addition to the technology transfer. PeptiDream is eligible to receive milestone payments upon the successful achievement of certain development milestones and royalties on future sales of products that arise from the agreements. Further financial terms have not been disclosed.

In the past six years, PeptiDream has established funded discovery collaborations with 15 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, and Shionogi, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, and Lilly.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.